

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)
(A company limited by guarantee)

**DIRECTORS' ANNUAL REPORT AND
FINANCIAL STATEMENTS**

YEAR ENDED 31 DECEMBER 2019

Company Registration Number SC597633
Charity Number SC048407

COMPANIES HOUSE

23 DEC 2020

EDINBURGH-MAILBOX



EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)
DIRECTORS' ANNUAL REPORT AND FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2019

CONTENTS	PAGE
Directors' annual report	1
Independent Examiner's report	7
Statement of financial activities incorporating income and expenditure account	8
Balance sheet	9
Notes to the financial statements	10

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

DIRECTORS' ANNUAL REPORT

YEAR ENDED 31 DECEMBER 2019

The directors are pleased to present their annual directors' report together with the financial statements of the charity for the year ending 31 December 2019 which are also prepared to meet the requirements for a trustees' report and accounts for Charity Law purposes.

The financial statements comply with the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Objects and activities

The objects of the charity are to foster, promote and advance the knowledge of inherited cancer including prevention, detection and clinical management and so advance health. In addition they aim to promote education and research devoted to the origin and causes, relief, cure, treatment, prevention lessening and alleviation of inherited cancer or any disease of an allied or similar nature. These objects are met, primarily, through arranging an annual conference.

Achievements and performance

A) Implementation of a Board

After the incorporation of the Society with 4 Directors (Julian Sampson, Pal Moller, John Burn and Gabriela Moeslein), it was timely to implement a board of Directors. The suggested board was agreed by vote at the membership meeting in Nice. Importantly there was a change of treasurer, addition of vice-chair, secretary, program director, and implementation of a Y(young)-EHTG.

B) The annual meeting 2019 took place in planned conjunction with the annual conference of UEG (United European Gastroenterologists) in Barcelona, however this did not develop in the intended collaborative fashion as in the previous year with ESCP. On the contrary, a competitive situation led to a lack of attendance of gastroenterologists at the EHTG meeting.

The conference venue was very suitable but more costly than in the pre-calculations. Additionally, the Catalan protests took place exactly at this time and caused disturbance of the meeting. With the EHTG meeting starting on Thursday and the blockade of Barcelona airport on Monday evening, the decision to host the meeting and not cancel or transfer to another city was most difficult. This affected attendance, but nevertheless an increase in participants from 165 in 2018 to 206 in 2019 was achieved.

Additionally, the attendance and active participation of renowned international speakers was intensified and increased.

C) Publication of all accepted abstracts in FAME(Familial Cancer)

D) Confirmation of an ongoing educational Grant from Promega

G) GGG-LS (LS-Guidelines) finalization with a third Delphi Round and in preparation for publication in BJS

H) PLSD - www.plsd.eu Expansion of collaborators, Implementation of DUA's

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

DIRECTORS' ANNUAL REPORT

YEAR ENDED 31 DECEMBER 2019

Financial review

There was a net operating surplus of €10,137 (2018: €7,199 deficit) for the year. At the year end, there were restricted funds of €Nil (2018: €Nil) and unrestricted funds of €2,937 in surplus (2018: €7,199 deficit).

Reserves policy

The company free reserves, being unrestricted funds, amounted to a surplus of €2,937 at the year-end (2018: €7,199). The directors would wish to build up reserves as a contingency against future events but appreciate that this is difficult in the current financial climate and may take some time. In the meantime the company has no significant ongoing commitments and is able to manage spending according to available funds. The directors are looking to set a specific reserves policy in the year ahead.

Risk management

The board has discussed the major risks to which the charity is exposed. These have been agreed and minuted, and action taken where relevant.

Principal Risk

3.1. The major risk continues to be financial and is intensified due to a loss incurred at the Barcelona 2019 annual meeting. This was not anticipated in advance, based on the calculations delivered by the secretariat. Therefore, there is an increased deficit in 2019 compared to 2018 taken forward.

3.2. The meeting was scientifically excellent and continued with the preferred format of working group sessions and plenary sessions. Unfortunately, the organization of the meeting by the secretariat provider was insufficient and caused quite some irritation among participants and also among the board members, especially those dealing with program. The effort required by the board during the meeting in order to resolve these issues was perceived by participants and did not contribute to professionalism of the conference. As a Society with an event organizer, this poses a risk for the development of the Society and raises issues regarding a lack of sponsorship for the meeting and also dissatisfaction of sponsors attending or contributing.

3.3. Commercial and costly venues may appear attractive, but certainly other (academic) venues would be much less costly and just as functional

Mitigation of Risk

3.1. The financial risk must be reduced for conference and a more precise prior calculation of costs is required. Realistic planning; taking all factors into account is mandatory.

3.2. An intense discussion with our secretariat and conference provider has been undertaken expressing the disappointments and flaws during and around conference. These have been minuted and coupled with suggestions for improvement to take forward. Also, a detailed review of cost and budget by the chair (GM) is envisaged for December at the office of the secretariat in Scotland.

3.3. First discussions to move the next face2face annual meeting to Sweden have been undertaken. First negotiations indicate that this idea can reasonably be developed further, avoiding costs for the conference venue

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

DIRECTORS' ANNUAL REPORT

YEAR ENDED 31 DECEMBER 2019

Plans for future periods

The Society needs to continue to grow its membership, increase global collaborative projects and generate sponsorship. Importantly, the annual meeting gains importance in generating visibility and sponsorship.

The next guidelines for PJS (Peutz-Jeghers-Syndrome) are underway.

COVID-19

The charity has been impacted by the Coronavirus pandemic affecting all charities and businesses. Whilst a lot of the charity's publications are released online, Covid-19 will affect future annual conferences. The directors are working with the charity's advisors to arrange alternative plans. The directors intend to support the charity through the pandemic and are confident that the charity remains a going concern for the foreseeable future.

Structure, governance and management

The organisation is a charitable company limited by guarantee, incorporated on 18 May 2018 and registered as a charity. The company was established under a Memorandum of Association, which sets out the objects and powers of the charitable company, and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.

Recruitment and appointment of directors

The directors of the company are also charity trustees for the purposes of charity law. Under the requirements of the Memorandum and Articles of Association directors are elected to serve for three years, after which they must be re-elected at the next Annual General Meeting. There are five directors on the Board, with three needed for a quorum.

The board wish to recruit directors so that the board has a range of skills of relevance to the charity. Individuals with a known interest in the theatre and drama are approached and invited into the board. The board currently has a broad mix of skills, including writing, finance, marketing, fundraising and education.

Directors induction and training

Any individual being appointed as a director will meet with the directors to discuss the charity, its operations and its future plans. The individual, at their first board meeting, is invited to address the board regarding their experience and skills with particular reference to the theatre.

Organisational structure

The board is ultimately responsible for the charity and meets regularly to discuss all matters relevant to the charity.

Day to day administration of the charity is delegated to Integrity International Events Ltd who liaise with the directors on various matters. The charity has no staff.

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

DIRECTORS' ANNUAL REPORT

YEAR ENDED 31 DECEMBER 2019

Reference and administrative information

Charity Name Known as	European Hereditary Tumour Group EHTG	
Charity registration number	SC048407	
Company registration number	SC597633	
Directors	Prof. Sir John Burns Gabriella Möselein Pål Møller Julia Sampson	
Treasurer	Ian Frayling Mev Dominguez	(resigned 14 January 2019) (appointed 14 January 2019)
Company Secretary	Integrity International Events Ltd	
Registered office	The Coach House 7 St Albans Road Edinburgh EH9 2PA	
Independent Examiner	Kevin Cattanach C.A. Whitelaw Wells Chartered Accountants 9 Ainslie Place Edinburgh EH3 6AT	

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

DIRECTORS' ANNUAL REPORT

YEAR ENDED 31 DECEMBER 2019

Statement of Responsibilities of the Board of Directors

Company law requires the directors to prepare financial statements for each financial year, which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including income and expenditure, for the financial year. In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going basis unless it is inappropriate to assume to presume that the charitable company will continue in business.

The directors are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities & Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). The directors are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the directors on 23 December 2020 and signed on their behalf by:



Gabriela Möslein
Director

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)
INDEPENDENT EXAMINER'S REPORT TO THE MEMBERS
YEAR ENDED 31 DECEMBER 2019

I report on the financial statements for the year ended 31 December 2019 set out on pages 7 to 13.

Respective responsibilities of the Trustees and the Independent Examiner

The charitable company's Directors are responsible for the preparation of the accounts in accordance with the terms of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). The charitable company's Directors consider that the audit requirement of Regulation 10(1) (a) to (c) of the Charities Accounts (Scotland) Regulations 2006 (as amended) does not apply. It is my responsibility to examine the accounts as required under section 44(1) (c) of the Act and to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination is carried out in accordance with Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended). An examination includes a review of the accounting records kept by the charitable company and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the Directors concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently I do not express an audit opinion on the view given by the accounts.

Independent examiner's statement

In the course of my examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that in any material respect the requirements:
 - to keep accounting records in accordance with Section 44 (1)(a) of the 2005 Act, Regulation 4 of the 2006 Accounts Regulations (as amended) and sections 386, 387, 477 and 482 of the Companies Act 2006 ; and
 - to prepare accounts which accord with the accounting records and comply with Regulation 8 of the 2006 Accounts Regulations (as amended).

have not been met; or
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Kevin Cattnach C.A.
Whitelaw Wells
Chartered Accountants
9 Ainslie Place
Edinburgh
EH3 6AT

23 December 2020

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

STATEMENT OF FINANCIAL ACTIVITIES incorporating INCOME AND EXPENDITURE ACCOUNT

YEAR ENDED 31 DECEMBER 2019

	Note	Unrestricted Funds €	2019 Total €	2018 Total €
<u>INCOME FROM:</u>				
Donations and grants	2	10,000	10,000	-
Charitable activities:				
Conference registration fees		69,195	69,195	53,986
Conference income		3,565	3,565	5,719
Sponsorship income		20,664	20,664	18,579
Accommodation income		42,585	42,585	34,225
Investments		12	12	-
		<hr/>	<hr/>	<hr/>
Total income		146,021	146,021	112,509
		<hr/>	<hr/>	<hr/>
<u>EXPENDITURE ON:</u>				
Charitable activities	3	135,884	135,884	119,936
		<hr/>	<hr/>	<hr/>
Total expenditure		135,884	135,884	119,936
		<hr/>	<hr/>	<hr/>
Net surplus/(expenditure)		10,137	10,137	(7,427)
Transfers between funds		-	-	-
Other recognised gains/(losses) – f/x gain		-	-	228
		<hr/>	<hr/>	<hr/>
Net movement in funds		10,137	10,137	(7,199)
Funds brought forward at 31 December 2018		(7,199)	(7,199)	-
		<hr/>	<hr/>	<hr/>
Funds carried forward at 31 December 2019		2,937	2,937	(7,199)
		<hr/>	<hr/>	<hr/>

The charity has no recognised gains or losses other than the results for the year as set out above.

All of the activities of the charity are classed as continuing.

The notes on pages 9 to 13 form part of these financial statements.

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

BALANCE SHEET

YEAR ENDED 31 DECEMBER 2019


	Note	2019 €	2018 €
CURRENT ASSETS			
Debtors	4	4,501	5,346
Cash at bank and in hand		13,874	29,273
		<hr/>	<hr/>
		18,375	34,619
CREDITORS: Amounts falling due within one year	5	(15,438)	(41,818)
		<hr/>	<hr/>
NET ASSETS		2,937	(7,199)
		<hr/>	<hr/>
FUNDS			
Unrestricted	6	2,937	(7,199)
		<hr/>	<hr/>
		2,937	(7,199)
		<hr/>	<hr/>

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 (the Act) and with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019)

For the year ended 31 December 2019 the company was entitled to exemption from audit under section 477 of the Act. No members have required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Act.

The directors acknowledge their responsibility for: (i) ensuring the company keeps accounting records which comply with sections 386 and 387 of the Act; and (ii) preparing accounts which give a true and fair view of the state of affairs of the company as at the end of its financial year, and of its profit and loss for the financial year in accordance with sections 394 and 395, and which otherwise comply with the requirements of the Act relating to accounts, so far as applicable to the company.

These financial statements were approved by the Directors on 25 September 2020 and are signed on their behalf by:



Gabriela Möselein
Director

The notes on pages 9 to 13 form part of these financial statements.

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER 2019

1. ACCOUNTING POLICIES

Basis of accounting

The accounts have been prepared under the historical cost convention and are in accordance with the Companies Act 2006, the Charities and Trustees Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019) and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

The accounts have been prepared in Euros which is the charity's functional currency.

The charity constitutes a public benefit entity as defined by FRS 102.

The charity has taken advantage of the exemption from the requirement to prepare a Statement of Cash Flows as permitted under FRS 102 and the Charities FRS 102 SORP.

Going concern

The Directors acknowledge the net liabilities position and deficit on general funds at the period end. The Directors are confident that liabilities will continue to be met as they fall due. The Directors are providing financial support when required and confirm they will continue to do so for the foreseeable future. Accordingly, the accounts have been prepared on a going concern basis.

Financial instruments

Financial instruments comprise financial assets and financial liabilities which are recognised when the company becomes a party to the contractual provisions of the instrument. Financial instruments are classified as "basic" in accordance with FRS102 and are accounted for at amortised cost using the effective interest method. The effective interest rate is the rate that exactly discounts estimated future cash flows over the life of the financial assets or liability to the net carrying amount on initial recognition. Discounting is not applied to short-term receivables and payables, where the effect is immaterial. Financial assets comprise cash, grants receivable and other debtors. Financial liabilities comprise other creditors and accruals.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity. Restricted funds are subject to restrictions on their expenditure imposed by the donor.

Income

Income received by way of grants, donations and gifts and is included in full in the Statement of Financial Activities when the charity has entitlement to the income. The value of services provided by volunteers has not been included.

Income from investments is included when receivable.

Income from charitable activities comprises performance fee and ticket sales, and is recognised when the performance is delivered.

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER 2019

1. ACCOUNTING POLICIES (cont)

Expenditure

All expenditure is included on an accruals basis and is recognised when there is a legal or constructive obligation to pay for expenditure. Costs have been directly attributed to one of the functional categories of resources expended in the Statement of Financial Activities in full. The charity is not registered for VAT and accordingly costs are shown gross of irrecoverable VAT.

Foreign exchange

Assets and liabilities in foreign currencies are translated into sterling at the rate of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the transaction date. Exchange rate differences are taken into account in arriving at movement in funds for the period.

2. INCOME FROM GRANTS AND DONATIONS

	Unrestricted Funds €	2019 Total €	2018 Total €
Promega Corporation	10,000	10,000	-
	<hr/>	<hr/>	<hr/>
	10,000	10,000	-
	<hr/>	<hr/>	<hr/>

Grant income totaled €10,000 (2018: €Nil). All other income was unrestricted in both the current and previous years.

3. EXPENDITURE ON CHARITABLE ACTIVITIES

	2019 €	2018 €
Conference costs	114,901	95,654
Printing, postage & stationery	3	12
Teleconference costs	1,288	565
Website costs	-	2,012
Secretary fees	321	5,466
Management fees	11,889	8,431
Professional fees	304	3,956
Bank charges	1,107	19
Service charges	1,556	1,603
Foreign exchange loss	2,165	-
<u>Governance costs</u>		
Independent Examination fees	2,350	2,218
	<hr/>	<hr/>
	135,884	119,936
	<hr/>	<hr/>

Expenditure in the year totaled €135,884 (2018: €119,936). The trustees consider there to be only one charitable activity

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER 2019

4. DEBTORS: Amounts falling due within one year

	2019	2018
	€	€
Trade debtors	2,260	136
Sundry debtors	1,974	-
VAT	267	5,210
	<hr/>	<hr/>
	4,501	5,346
	<hr/>	<hr/>

5. CREDITORS: Amounts falling due within one year

	2019	2018
	€	€
Trade creditors	-	2,562
Accruals	4,761	22,870
Deferred income (note below)	150	425
Directors loan account	10,527	10,527
Other creditors	-	5,434
	<hr/>	<hr/>
	15,438	41,818
	<hr/>	<hr/>

Deferred income

	€
Opening balance as at 1 January 2019	425
Released in the year	(425)
Closing balance as at 31 December 2019	150
	<hr/>
	150
	<hr/>

EH TG (EUROPEAN HEREDITARY TUMOUR GROUP)

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER 2019

6. STATEMENT OF FUNDS

	At 1 January 2019 €	Income €	Expenditure €	Transfers €	At 31 December 2019 €
Unrestricted funds					
General	(7,199)	146,021	(135,884)	-	2,937
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
	(7,199)	146,021	(135,884)	-	2,937
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>

General funds

Unrestricted funds, which comprise the general funds, are expendable at the discretion of the directors, in furtherance of the objects of the company.

	At 18 May 2018 €	Income €	Expenditure €	Transfers €	At 31 December 2018 €
Unrestricted funds					
General	-	112,737	(119,936)	-	(7,199)
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
	-	112,737	(119,936)	-	(7,199)
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>

EHTG (EUROPEAN HEREDITARY TUMOUR GROUP)

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER 2019

7. ANALYSIS OF NET ASSETS BY FUND

	Unrestricted Funds €	Total Funds €
Current assets	18,375	18,375
Current liabilities	(15,438)	(15,438)
	<hr/>	<hr/>
Net liabilities at 31 December 2019	2,937	2,937
	<hr/>	<hr/>

	Unrestricted Funds €	Total Funds €
Current assets	34,619	34,619
Current liabilities	(41,818)	(41,818)
	<hr/>	<hr/>
Net assets at 31 December 2018	(7,199)	(7,199)
	<hr/>	<hr/>

8. RELATED PARTY TRANSACTIONS

The directors provided loans of €10,572 to the company in the previous year. The balance outstanding at the year end was €10,572 (2018 - €10,572). None of the directors received any remuneration, nor were reimbursed any expenses.

9. COMPANY LIMITED BY GUARANTEE

The members have indicated that they will contribute £2,000 each on winding up the company. There are 4 members.

10. TAXATION

The charitable company is recognised as having charitable status by H M Revenue & Customs for taxation purposes. As a result no liability to taxation is anticipated on any of its income.